1015 related articles for article (PubMed ID: 33404891)
41. Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays.
Semmler G; Traugott MT; Graninger M; Hoepler W; Seitz T; Kelani H; Karolyi M; Pawelka E; Aragón de La Cruz S; Puchhammer-Stöckl E; Aberle SW; Stiasny K; Zoufaly A; Aberle JH; Weseslindtner L
J Clin Microbiol; 2021 Apr; 59(5):. PubMed ID: 33602698
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of High-Throughput SARS-CoV-2 Serological Assays in a Longitudinal Cohort of Patients with Mild COVID-19: Clinical Sensitivity, Specificity, and Association with Virus Neutralization Test.
Bal A; Pozzetto B; Trabaud MA; Escuret V; Rabilloud M; Langlois-Jacques C; Paul A; Guibert N; D'Aubarède-Frieh C; Massardier-Pilonchery A; Fabien N; Goncalves D; Boibieux A; Morfin-Sherpa F; Pitiot V; Gueyffier F; Lina B; Fassier JB; Trouillet-Assant S;
Clin Chem; 2021 Apr; 67(5):742-752. PubMed ID: 33399823
[TBL] [Abstract][Full Text] [Related]
43. Clinical characteristics and antibody response to SARS-CoV-2 spike 1 protein using VITROS Anti-SARS-CoV-2 antibody tests in COVID-19 patients in Japan.
Nagura-Ikeda M; Imai K; Kubota K; Noguchi S; Kitagawa Y; Matsuoka M; Tabata S; Miyoshi K; Ito T; Tamura K; Maeda T
J Med Microbiol; 2021 Apr; 70(4):. PubMed ID: 33861191
[No Abstract] [Full Text] [Related]
44. Correlation between SARS-COV-2 antibody screening by immunoassay and neutralizing antibody testing.
Mendrone-Junior A; Dinardo CL; Ferreira SC; Nishya A; Salles NA; de Almeida Neto C; Hamasaki DT; Facincani T; de Oliveira Alves LB; Machado RRG; Araujo DB; Durigon EL; Rocha V; Sabino EC
Transfusion; 2021 Apr; 61(4):1181-1190. PubMed ID: 33491194
[TBL] [Abstract][Full Text] [Related]
45. Multiplex assessment of SARS-CoV-2 antibodies improves assay sensitivity and correlation with neutralizing antibodies.
Cook N; Xu L; Hegazy S; Wheeler BJ; Anderson AR; Critelli N; Yost M; McElroy AK; Shurin MR; Wheeler SE
Clin Biochem; 2021 Nov; 97():54-61. PubMed ID: 34453893
[TBL] [Abstract][Full Text] [Related]
46. SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays.
Allen N; Brady M; Carrion Martin AI; Domegan L; Walsh C; Houlihan E; Kerr C; Doherty L; King J; Doheny M; Griffin D; Molloy M; Dunne J; Crowley V; Holmes P; Keogh E; Naughton S; Kelly M; O'Rourke F; Lynagh Y; Crowley B; de Gascun C; Holder P; Bergin C; Fleming C; Ni Riain U; Conlon N;
Microbiol Spectr; 2021 Oct; 9(2):e0039121. PubMed ID: 34585976
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of 3 SARS-CoV-2 IgG Antibody Assays and Correlation with Neutralizing Antibodies.
Rychert J; Couturier MR; Elgort M; Lozier BK; La'ulu S; Genzen JR; Straseski JA; Delgado JC; Slev PR
J Appl Lab Med; 2021 Apr; 6(3):614-624. PubMed ID: 33064790
[TBL] [Abstract][Full Text] [Related]
48. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
49. Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers.
Heaney CD; Pisanic N; Randad PR; Kruczynski K; Howard T; Zhu X; Littlefield K; Patel EU; Shrestha R; Laeyendecker O; Shoham S; Sullivan D; Gebo K; Hanley D; Redd AD; Quinn TC; Casadevall A; Zenilman JM; Pekosz A; Bloch EM; Tobian AAR
J Clin Virol; 2021 Dec; 145():104997. PubMed ID: 34695724
[TBL] [Abstract][Full Text] [Related]
50. Head-to-head comparison of two rapid high-throughput automated electrochemiluminescence immunoassays targeting total antibodies to the SARS-CoV-2 nucleoprotein and spike protein receptor binding domain.
Poljak M; Oštrbenk Valenčak A; Štamol T; Seme K
J Clin Virol; 2021 Apr; 137():104784. PubMed ID: 33711693
[TBL] [Abstract][Full Text] [Related]
51. Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays.
Weidner L; Gänsdorfer S; Unterweger S; Weseslindtner L; Drexler C; Farcet M; Witt V; Schistal E; Schlenke P; Kreil TR; Jungbauer C
J Clin Virol; 2020 Aug; 129():104540. PubMed ID: 32652475
[TBL] [Abstract][Full Text] [Related]
52. Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2.
Bonhomme ME; Bonhomme CJ; Strelow L; Chaudhari A; Howlett A; Breidenbach C; Hester J; Hammond C; Fuzy M; Harvey L; Swanner V; Ellis J; Greway RR; Pisciella VA; Green T; Kierstead L
PLoS One; 2022; 17(2):e0262922. PubMed ID: 35130298
[TBL] [Abstract][Full Text] [Related]
53. Clinical performance of three fully automated anti-SARS-CoV-2 immunoassays targeting the nucleocapsid or spike proteins.
Favresse J; Cadrobbi J; Eucher C; Elsen M; Laffineur K; Dogné JM; Douxfils J
J Med Virol; 2021 Apr; 93(4):2262-2269. PubMed ID: 33200836
[TBL] [Abstract][Full Text] [Related]
54. Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan.
Yokoyama R; Kurano M; Morita Y; Shimura T; Nakano Y; Qian C; Xia F; He F; Kishi Y; Okada J; Yoshikawa N; Nagura Y; Okazaki H; Moriya K; Seto Y; Kodama T; Yatomi Y
PLoS One; 2021; 16(3):e0247711. PubMed ID: 33661990
[TBL] [Abstract][Full Text] [Related]
55. SARS Coronavirus-2 Microneutralisation and Commercial Serological Assays Correlated Closely for Some but Not All Enzyme Immunoassays.
Walker GJ; Naing Z; Ospina Stella A; Yeang M; Caguicla J; Ramachandran V; Isaacs SR; Agapiou D; Bull RA; Stelzer-Braid S; Daly J; Gosbell IB; Hoad VC; Irving DO; Pink JM; Turville S; Kelleher AD; Rawlinson WD
Viruses; 2021 Feb; 13(2):. PubMed ID: 33557418
[TBL] [Abstract][Full Text] [Related]
56. A performance comparison of two (electro) chemiluminescence immunoassays for detection and quantitation of serum anti-spike antibodies according to SARS-CoV-2 vaccination and infections status.
Camacho J; Albert E; Zulaica J; Álvarez-Rodríguez B; Rusu L; Olea B; Alcaraz MJ; Geller R; Giménez E; Navarro D
J Med Virol; 2023 Jan; 95(1):e28397. PubMed ID: 36504019
[TBL] [Abstract][Full Text] [Related]
57. A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System.
Angeloni S; Cameron A; Pecora ND; Dunbar S
J Vis Exp; 2021 Apr; (170):. PubMed ID: 33900295
[TBL] [Abstract][Full Text] [Related]
58. Neutralizing antibody responses following natural SARS-CoV-2 infection: Dynamics and correlation with commercial serologic tests.
Montesinos I; Dahma H; Wolff F; Dauby N; Delaunoy S; Wuyts M; Detemmerman C; Duterme C; Vandenberg O; Martin C; Hallin M
J Clin Virol; 2021 Nov; 144():104988. PubMed ID: 34607239
[TBL] [Abstract][Full Text] [Related]
59. Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients.
Chansaenroj J; Yorsaeng R; Posuwan N; Puenpa J; Sudhinaraset N; Chirathaworn C; Poovorawan Y
Virol J; 2021 Mar; 18(1):52. PubMed ID: 33750394
[TBL] [Abstract][Full Text] [Related]
60. Comparability of six different immunoassays measuring SARS-CoV-2 antibodies with neutralizing antibody levels in convalescent plasma: From utility to prediction.
Lamikanra A; Nguyen D; Simmonds P; Williams S; Bentley EM; Rowe C; Otter AD; Brooks T; Gilmour K; Mai A; Dadhra J; Csatari M; Ziyenge S; Oliveira M; Ploeg R; Tsang P; Zambon M; Gopal R; Xiao JH; Townsend A; Roberts D; Harvala H
Transfusion; 2021 Oct; 61(10):2837-2843. PubMed ID: 34342366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
